These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 38937182)

  • 1. Randomized, blind, controlled phase III clinical trial: Assessing the immunogenicity and safety of freeze-dried human rabies vaccine (vero cell) with a 4-dose regimen (2-1-1) in a 10-60 year-old demographic.
    Jin F; Zhu L; Wang Y; Qin G; Tian Y; Xie Y; Jin H; Zhang Y; Wang L; Li J; Wu Z; Sheng Y; Shi L; Yang G; Zhao Z; Chen L; Chen P; Jiang Z; Yu J; Gao Z; Li Q; Wu X; Miao L
    Vaccine; 2024 Oct; 42(23):126059. PubMed ID: 38937182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized open-labeled study to demonstrate the non-inferiority of purified chick-embryo cell rabies vaccine administered in the Zagreb regimen (2-1-1) compared with the Essen regimen in Chinese adults.
    Ma J; Wang H; Li J; Chang L; Xie Y; Liu Z; Zhao Y; Malerczyk C
    Hum Vaccin Immunother; 2014; 10(10):2805-12. PubMed ID: 25483635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intradermal post-exposure rabies vaccination with purified Vero cell rabies vaccine: Comparison of a one-week, 4-site regimen versus updated Thai Red Cross regimen in a randomized non-inferiority trial in the Philippines.
    Quiambao BP; Ambas C; Diego S; Bosch Castells V; Korejwo J; Petit C; Houillon G
    Vaccine; 2019 Apr; 37(16):2268-2277. PubMed ID: 30890382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and Safety of a Purified Vero Rabies Vaccine-Serum Free, Compared With 2 Licensed Vaccines, in a Simulated Rabies Post-Exposure Regimen in Healthy Adults in France: A Randomized, Controlled, Phase 3 Trial.
    Pineda-Peña AC; Jiang Q; Petit C; Korejwo-Peyramond J; Donazzolo Y; Latreille M; Homery MC; Babin V; Benamor S; Pichon S; Guinet-Morlot F; Minutello AM
    Clin Infect Dis; 2024 Jun; 78(6):1748-1756. PubMed ID: 38478634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of rabies antibody 5 years after postexposure prophylaxis with vero cell antirabies vaccine and antibody response to a single booster dose.
    Zhang X; Zhu Z; Wang C
    Clin Vaccine Immunol; 2011 Sep; 18(9):1477-9. PubMed ID: 21752947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of purified vero cell rabies vaccine (PVRV) produced by Liaoning Cheng Da Co. under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese adults aged 50 and above.
    Wang J; Luo F; Feng Z; Li L; Bai Y; Ai X; Ma J; Zhang Z; Shi N
    Hum Vaccin Immunother; 2017 Jan; 13(1):144-150. PubMed ID: 28045585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Safety and immunogenicity of freeze-dried rabies vaccine (Vero-cells) for human use in healthy people aged 9-65 years].
    Huang LL; Xie ZQ; Zhang W; Zhang K; Wang YX; Wang ZQ; Wu XJ; Liu DM
    Zhonghua Yu Fang Yi Xue Za Zhi; 2023 Feb; 57(2):222-228. PubMed ID: 36797580
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety and immunogenicity of two freeze-dried Vero cell rabies vaccines for human use in post-exposure prophylaxis.
    Wang LY; Sun MP; Zhang XC; Suo LD; Xu RH; Zou YJ; Zuo LB; Qi H
    Vaccine; 2011 Mar; 29(15):2679-81. PubMed ID: 21296694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10-50 years old: Randomized, blinded, parallel controlled phase III clinical study.
    Huang X; Liang J; Huang L; Nian X; Chen W; Zhang J; Xu X; Lin X; Wang Y; Shi J; Jia L; Li Q; Wang Q; Duan K; Li X; Ji Y; Peng F; Zhang W; Xie Z; Wang Y; Yang X
    Hum Vaccin Immunother; 2023 Dec; 19(1):2211896. PubMed ID: 37249318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.
    Kerdpanich P; Chanthavanich P; De Los Reyes MR; Lim J; Yu D; Ama MC; Mojares Z; Casula D; Arora AK; Pellegrini M
    PLoS Negl Trop Dis; 2018 Jun; 12(6):e0006340. PubMed ID: 29874228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II randomized study to determine the safety and immunogenicity of the novel PIKA rabies vaccine containing the PIKA adjuvant using an accelerated regimen.
    Kalimuddin S; Wijaya L; Chan YFZ; Wong AWL; Oh HML; Wang LF; Kassim JA; Zhao J; Shi Z; Low JG
    Vaccine; 2017 Dec; 35(51):7127-7132. PubMed ID: 29174316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and safety of purified vero cell-cultured rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in the healthy Chinese subjects: a randomized, double-blind, positive controlled phase 3 clinical trial.
    Shen H; Wang Z; Yang B; Cai K; Jiang C; Xie R; Xiao H; Ren Q; Qi Z; Li J; Li Q; Ye J; Zhan F
    Hum Vaccin Immunother; 2021 Feb; 17(2):351-357. PubMed ID: 32783769
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.
    Li R; Li Y; Wen S; Wen H; Nong Y; Mo Z; Xie F; Pellegrini M
    Hum Vaccin Immunother; 2015; 11(2):435-42. PubMed ID: 25692350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological Effect of aGV Rabies Vaccine Administered Using the Essen and Zagreb Regimens: A Double-Blind, Randomized Clinical Trial.
    Miao L; Shi L; Yang Y; Yan K; Sun H; Mo Z; Li L
    Viral Immunol; 2018 Apr; 31(3):242-248. PubMed ID: 29394147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-marketing immunogenicity and safety of a lyophilized purified human diploid cell rabies vaccine produced from microcarrier cultures: a randomized clinical trial.
    Zhou X; Wu X; Cai Y; Cao S; Zhu X; Lv Q; Chen H; Shi L; Li J; Wang X; Li Y; Zhou R
    Hum Vaccin Immunother; 2019; 15(4):828-833. PubMed ID: 30457436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A next-generation, serum-free, highly purified Vero cell rabies vaccine is safe and as immunogenic as the reference vaccine Verorab® when administered according to a post-exposure regimen in healthy children and adults in China.
    Li R; Huang L; Li J; Mo Z; He B; Wang Y; Wu X; Minutello M; Guinet-Morlot F; Pichon S
    Vaccine; 2013 Dec; 31(50):5940-7. PubMed ID: 24148575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, safety and antibody persistence of a purified vero cell cultured rabies vaccine (Speeda) administered by the Zagreb regimen or Essen regimen in post-exposure subjects.
    Shi N; Zhang Y; Zheng H; Zhu Z; Wang D; Li S; Li Y; Yang L; Zhang J; Bai Y; Lu Q; Zhang Z; Luo F; Yu C; Li L
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28121231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen.
    Ambrozaitis A; Laiskonis A; Balciuniene L; Banzhoff A; Malerczyk C
    Vaccine; 2006 May; 24(19):4116-21. PubMed ID: 16545510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of rabies immunogenicity and tolerability following a purified chick embryo cell rabies vaccine administered concomitantly with a Japanese encephalitis vaccine.
    Jelinek T; Cramer JP; Dieckmann S; Hatz C; Paulke-Korinek M; Alberer M; Reisinger EC; Costantini M; Gniel D; Bosse D; Lattanzi M
    Travel Med Infect Dis; 2015; 13(3):241-50. PubMed ID: 26005163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simulated, randomized study on the safety and immunogenicity of three consecutive commercial-scale batches of the CTN-1V strain human rabies vaccine to verify the inter-batch consistency.
    Zhou L; Liu J; Li J; Liu X; Zhang J; Nie F; Chen J; Chai J; Lv J; Wang M; Yu J; Wu W; Li Y; Zhang Y
    Hum Vaccin Immunother; 2022 Nov; 18(6):2138049. PubMed ID: 36409064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.